# Adjuvant Palliative Capecitabine and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Biliary Tract Cancer

> **NCT00073905** · PHASE2 · COMPLETED · sponsor: **Swiss Cancer Institute** · enrollment: 44 (actual)

## Conditions studied

- Extrahepatic Bile Duct Cancer
- Gallbladder Cancer
- Liver Cancer
- Pain

## Interventions

- **DRUG:** capecitabine plus gemcitabine

## Key facts

- **NCT ID:** NCT00073905
- **Lead sponsor:** Swiss Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-04
- **Primary completion:** 2006-06
- **Final completion:** 2009-01
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2012-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00073905

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00073905, "Adjuvant Palliative Capecitabine and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Biliary Tract Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00073905. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*